IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Álvarez H
  • Gutiérrez-Valencia A
  • Mariño A
  • Saborido-Alconchel A
  • Calderón-Cruz B
  • Pérez-González A
  • Alonso-Domínguez J
  • Martínez-Barros I
  • Gallego-Rodríguez M
  • Moreno S
  • Aldamiz T
  • Bernal E
  • Galera C
  • Llibre JM
  • Poveda E

Grupos

Abstract

BACKGROUND: Interferon-inducible protein-10 (IP-10) and monokine induced by interferon-gamma (MIG) are chemokines recognized as inflammatory biomarkers during HIV-1 infection. We assessed their early and long-term dynamics after initiation of antiretroviral treatment (ART). METHODS: Persons with HIV-1 (PWH) aged>18 years starting their first ART in 2015-2021 in a prospective cohort (n=73) were included. IP-10 and MIG plasma levels were quantified using a multiplexed bead-based assay. RESULTS: IP-10 and MIG plasma levels showed a significant and consistent reduction following ART (80% integrase inhibitor [INSTI]-based) initiation, starting at day 20 and maintained throughout the study period (48 months), paralleling the HIV-1 RNA decay and CD4+ count recovery (p<0·001). At baseline, PWH= 50 years, CDC stage C and CD4+ count<350cells/mm(3) had higher levels of IP-10 (p=0·022, p=0·001 and p=0·002, respectively) and MIG (p<0·001, p=0·024 and p=0·069, respectively). All of them matched their counterparts several months following ART initiation. MIG levels showed a greater decrease at day 10 in those treated with INSTI (p=0·038). Low-level HIV-1 viremia did not impact MIG or IP-10 levels. CONCLUSION: Plasma IP-10 and MIG showed an early significant decline following ART initiation, with greater early declines in MIG levels in INSTI-based regimens. These findings suggest a strong impact of HIV-1 viremia on IP-10 and MIG levels.

Copyright © 2023 Álvarez, Gutiérrez-Valencia, Mariño, Saborido-Alconchel, Calderón-Cruz, Pérez-González, Alonso-Domínguez, Martínez-Barros, Gallego-Rodríguez, Moreno, Aldamiz, Montero-Alonso, Bernal, Galera, Llibre and Poveda.

Datos de la publicación

ISSN/ISSNe:
1664-3224, 1664-3224

Frontiers in Immunology  FRONTIERS MEDIA SA

Tipo:
Article
Páginas:
1257725-1257725
PubMed:
37920466
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,331 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 8

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • HIV-1 viral decay; IP-10; MIG; antiretroviral treatment; biomarkers

Compartir